Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene ciloleucel versus standard of care in relapsed/refractory DLBCL
NCT03391466Phase 3Completed
- Sponsor
- Kite Pharma
- Start
- Jan 2018
- Primary completion
- Mar 2021
- Modality
- CAR-T Cells
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Axicabtagene Ciloleucel Treatment with Standard of Care Therapy (2 arms). Primary endpoint: Event Free Survival at 24.9 months. Started Jan 2018; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03391466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391466.